Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Slide: 40 of 50

Summary of Adverse Effects of Pharmacological Interventions

Tolerability of pharmacological interventions, represented by the rate of discontinuation of treatment due to adverse effects, includes:

No statistically significant difference from placebo (darifenacin, tolterodine) and less than 10 percent difference in the rate from placebo (discontinuations per 1,000: solifenacin, 10; trospium, 20; fesoterodine, 30; oxybutynin, 63). The strength of evidence for these findings is high.

Dry mouth is the most common adverse effect (100 per 1,000 treated patients), followed by constipation (47 to 83 per 1,000 treated patients).

Dry eye, blurred vision, and dyspepsia are less frequent, with fewer than 50 events per 1,000 treated patients, with the exception of dyspepsia with oxybutynin at 80 per 1,000 treated patients.